Cartilage repair is the largest unmet need in orthopedic sports medicine today. Cartilage has very little blood supply, and major damage often doesn’t heal well. Patients with cartilage damage can experience pain, stiffness and swelling in their joint. Athletes in high impact sports have a higher risk of damaging cartilage in their joints. If left untreated, damaged cartilage can lead to long-term, irreversible joint damage.
The most common treatment for cartilage damage is microfracture surgery. Small holes made in the bone under the damaged cartilage allow a blood clot to form. The clot begins to form new cartilage. But, this procedure can lead to the formation of a weaker type of cartilage. As a result, the treatment often provides only short-term relief. This means more surgeries may be needed in the future.
TRIA is participating in a clinical trial for a new kind of treatment. An implant called GelrinC may help the body regrow cartilage in the knee. Surgeons implant GelrinC as a liquid. It completely fills the cartilage defect in the knee. It then cures into a gel that allows the body’s stem cells to settle on its surface. The body absorbs the GelrinC over a period of 6-12 months and replaces it with new cartilage tissue. In Europe, an early clinical trial has shown positive results. The new cartilage tissue provided excellent improvement in pain and function.
You may be eligible to take part in this clinical trial. You must be between 18 and 50 years old and have pain in only one knee caused by damaged articular cartilage. Visit www.mykneestudy.com or call 833-430-8686 to learn more. Patients go home soon after the surgery, which only requires a small incision. And patients can resume daily activities in 8-10 weeks.